Establishment of a method for measuring plasma sCLEC-2 and its clinical application aiming to prevent arterial thrombosis

我们推测，血浆中可溶性CLEC-2浓度是体内血小板活化的良好标志物，可作为防治心肌梗死和脑梗塞的有用生物标志物。我们建立了检测sCLEC-2的酶联免疫吸附试验体系，发现sCLEC-2是由血小板活化产生的。此外，急性冠脉综合征患者血浆sCLEC-2水平显著升高，提示sCLEC-2是防治动脉血栓形成的有用生物标志物。

We hypothesized that concentration of plasma soluble CLEC-2 is a good marker for platelet activation in vivo and that it could be a useful biomarker for prevention and treatment for myocardial and cerebral infarction. We established ELISA system to measure sCLEC-2 and found that sCLEC-2 isgenerated upon platelet activation. Moreover, plasma sCLEC-2 is significantly increased in patients of acute coronary syndrome, suggesting that sCLEC-2 is a useful biomarker for prevention and treatment for arterial thrombosis.